1. Home
  2. CDT vs LRHC Comparison

CDT vs LRHC Comparison

Compare CDT & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • LRHC
  • Stock Information
  • Founded
  • CDT 2019
  • LRHC 2004
  • Country
  • CDT United States
  • LRHC United States
  • Employees
  • CDT N/A
  • LRHC N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • LRHC
  • Sector
  • CDT Health Care
  • LRHC
  • Exchange
  • CDT Nasdaq
  • LRHC Nasdaq
  • Market Cap
  • CDT 3.1M
  • LRHC 2.9M
  • IPO Year
  • CDT N/A
  • LRHC 2023
  • Fundamental
  • Price
  • CDT $2.15
  • LRHC $1.84
  • Analyst Decision
  • CDT
  • LRHC
  • Analyst Count
  • CDT 0
  • LRHC 0
  • Target Price
  • CDT N/A
  • LRHC N/A
  • AVG Volume (30 Days)
  • CDT 57.3K
  • LRHC 325.7K
  • Earning Date
  • CDT 11-14-2025
  • LRHC 11-19-2025
  • Dividend Yield
  • CDT N/A
  • LRHC N/A
  • EPS Growth
  • CDT N/A
  • LRHC N/A
  • EPS
  • CDT N/A
  • LRHC N/A
  • Revenue
  • CDT N/A
  • LRHC $78,660,186.00
  • Revenue This Year
  • CDT N/A
  • LRHC N/A
  • Revenue Next Year
  • CDT N/A
  • LRHC N/A
  • P/E Ratio
  • CDT N/A
  • LRHC N/A
  • Revenue Growth
  • CDT N/A
  • LRHC 24.52
  • 52 Week Low
  • CDT $1.61
  • LRHC $1.75
  • 52 Week High
  • CDT $2,198.40
  • LRHC $95.20
  • Technical
  • Relative Strength Index (RSI)
  • CDT 47.44
  • LRHC 25.84
  • Support Level
  • CDT $1.61
  • LRHC $1.82
  • Resistance Level
  • CDT $2.84
  • LRHC $3.19
  • Average True Range (ATR)
  • CDT 0.21
  • LRHC 0.52
  • MACD
  • CDT -0.08
  • LRHC -0.08
  • Stochastic Oscillator
  • CDT 39.19
  • LRHC 5.42

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About LRHC La Rosa Holdings Corp.

La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.

Share on Social Networks: